CRS 2017: Management of Resistant Hypertension

October 22, 2017 at 9:15am

It is important to differentiate between apparent and true resistant hypertension, a discrimination that Robert D Brook, MD will discuss further in his presentation, “Management of Resistant Hypertension.”

Firstly, Brook will define resistant hypertension and how it is related to controlled, refractory, and uncontrolled hypertension. He will go on to examine issues that could affect the measurement of blood pressure, including larger arms, “white-coat” resistance, and “cuff-inflation” response, and how to deal with these challenges.

Next, Brook will discuss the management of common causes of resistant hypertension, particularly hyperaldosteronism, as well as how to improve medication and lifestyle adherence in patients with resistant hypertension.

Brook will conclude with a discussion of optimal medical management strategies, particularly mineralocorticoid blockade, as well as how to consolidate a patients regimen to essential medications, and other novel approaches to treatment.

—Michael Potts

Reference:

Brook RD. Management of resistant hypertension [presented at Cardiometabolic Risk Summit 2017]. Dallas, Texas. October 22, 2017.